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Edited by Horst FeldmannAbstract Doxorubicin, cis-diamminedichloroplatinum (II) and
5-ﬂuorouracil used in chemotherapy induce apoptosis in Hep3B
cells in the absence of p53, p73, and functional Fas. Since medi-
ators remain unknown, the requirement of PKC delta (PKCd)
and c-Abl was investigated. Suppression of c-Abl or PKCd
expression using SiRNAs impaired PARP cleavage, Gleevec
and/or rottlerin inhibited the induction of the subG1 phase and
the increase of reactive oxygen species level. Co-precipitations
and phosphorylations to mitochondria of c-Abl, PKCd and
Bcl-XL/s were induced. A depolarization of the mitochondrial
membrane and activations of caspase-2 and -9 were observed.
We propose that, in the absence of p53, p73 and Fas, genotoxic
drugs could require both PKCd and c-Abl to induce apoptosis
through the mitochondrial pathway.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Genotoxic drugs, doxorubicin (DOX), cisplatin (cDDP) and
5-ﬂuorouracil (5-FU) are currently used in chemotherapy and
known to induce apoptosis [1,2]. DOX and cDDP mediate
apoptosis via FasL/Fas/caspase-8 and mitochondria/caspase-
9 pathways. 5-FU seems to mainly involve the Fas L/Fas path-
way. These drugs also stabilize the tumor suppressor p53,
which activates pro-apoptotic proteins. The p53 family mem-
ber p73, can also trigger DNA damage-induced apoptosis
[3]. We have previously shown that in the human hepatocarci-
noma cell line Hep3B, these genotoxic drugs induce apoptosis
in the absence of p53, p73 (personal communication) and func-
tional Fas receptor [4–7]. The mediators involved in the initia-
tion of this apoptosis remain unknown. Recent ﬁndings haveAbbreviations: DOX, doxorubicin; cDDP, cis-diamminedichloroplati-
num (II); 5-FU, 5-ﬂuorouracil; PKCd, PKC delta; MMP, mitochon-
drial membrane permeabilization; cyt c, cytochrome c; ROS, reactive
oxygen species; PI, propidium iodide; DAPI, di-amidino-phenyl-ind-
ole; tert-butyl, tert-butylhydroperoxide; CCCP, carbonyl-cyanide-
m-chloro-phenyl-hydrazone
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doi:10.1016/j.febslet.2006.03.089suggested a possible role of the Tyr protein kinase c-Abl [8].
Its N-terminal region contains Src homology domains interact-
ing with the Ser/Thr protein kinase PKC delta (PKCd) [8–10].
Whatever the nature of the stress, the stimulation of PKCd
seems to be necessary for the activation of c-Abl. On the basis
of these ﬁndings, we investigated, in this study, a possible
requirement of both, c-Abl and PKCd in the induction of
apoptosis by DOX, cDDP and 5-FU in Hep3B cells. We used
RNA interference against c-Abl and PKCd, Gleevec which
inhibits c-Abl by blocking its ATP binding site [11] and rott-
lerin which inhibits PKCd at a certain range of concentrations
[12].2. Materials and methods
2.1. Cell culture and drug exposure
The human hepatocarcinoma cell line Hep3B (ATCC) was grown in
DMEM, 10% fetal calf serum, penicillin/streptomycin, and exposed or
not for 90 min to 24 h with 1 lM DOX, 1 mM cDDP or 1 mM 5-FU
(Sigma–Aldrich, St. Quentin Fallavier, France) as already described
[5,6]. Prior to the drug addition, some cells were pretreated for
15 min to 24 h with 10 lM Gleevec (Novartis Pharma AG, Basel,
Switzerland) and/or 5 lM rottlerin (Sigma–Aldrich) as usually per-
formed in the literature [11,12].
2.2. Cell survival and apoptosis analysis
Cell survival was analyzed by the MTT (Sigma–Aldrich) assay as al-
ready described [6]. Floating and adherent cells stained with propidium
iodide (PI) (Invitrogen, Cergy Pontoise, France) were analyzed for
subG1 in a ﬂow cytometer (Beckman Coulter) [6]. The presence of
chromatin condensation was analyzed under UV-light after cell stain-
ing with di-amidino-phenyl-indole (DAPI) (Sigma–Aldrich). PARP
cleavage was studied by Western blotting on nuclear extracts using a
mouse monoclonal anti-PARP antibody (PharMingen, Lexington,
KY).
2.3. Caspase activity assays
The activities of caspase-2 and caspase-9 were measured using Z-
VDVAD-AFCorAC-LEHD-AFCﬂuorogenic substrates (Calbiochem,
Nottingham, UK) in a ﬂuorimeter (Fluostar, BMGLabtechnologies) at
the excitation/emission wavelengths of 400/505 nm [6].
2.4. Measurement of intracellular ROS level and MMP decrease
Intracellular reactive oxygen species (ROS) level was measured by
ﬂuorimetry using the DCFH-DA probe (Sigma–Aldrich) as previously
described [6]. The mitochondrial membrane permeabilization (MMP)
(DWm) decrease was determined as following. Brieﬂy, ﬂoating and
adherent cells exposed or not for 24 h to drugs were harvested andblished by Elsevier B.V. All rights reserved.
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darkness. Then, cells were incubated for 15 min with 1 lg/ml PI to gate
out dead cells. The ﬂuorescence intensities of DiOC6 were analyzed in a
ﬂow cytometer (Beckman Coulter). The depolarizing agent carbonyl-
cyanide-m-chloro-phenyl-hydrazone (CCCP) (200 lM) (Sigma–Al-
drich), incubated 10 min before adding DiOC6, was used as a positive
reference control (100%).
2.5. Isolation of subcellular extracts and immunoprecipitations
Nuclear proteins were extracted for PARP cleavage analysis and
mitochondria isolated as described [5,13]. For puriﬁcation, mitochon-
drial fractions were centrifuged for 30 min at 13000 · g on 1 ml of 1 M
sucrose and solubilized using 0.1% NP40. Immunoprecipitations using
mouse monoclonal anti-c-Abl (24–11) (Santa Cruz Biotechnology,
Santa Cruz, CA) or rabbit polyclonal anti-PKCd (Upstate Biotechnol-
ogy, Charlottesville, VA) antibodies and agarose protein A/G Plus
beads were performed according to the Tebu-bio protocol (Le Perray
en Yvelines, France).
2.6. Western blot and phosphorylation analyses
Proteins issued from cells, subcellular fractions or immunoprecipita-
tions were transferred onto nitrocellulose membrane from 7–20%
SDS–PAGE. Western blots were revealed with rabbit polyclonal
anti-PKCd, anti-c-Abl or anti-Bcl-XL/s (Transduction Laboratories,
Lexington, KY) antibodies. Mouse anti-actin antibody (Santa Cruz)
was used as control. Anti-porin (Calbiochem) and anti-COXIV
(Molecular Probes, Invitrogen) antibodies were used as strictly
markers of mitochondria. For the phosphorylation analyses, rabbit
anti-phosphoserine polyclonal and mouse anti-phosphotyrosine mono-
clonal antibodies (Chemicon International) were used.
2.7. Transfection with SiRNAs
Twenty millions Hep3B cells were washed in serum-free OptiMEM
without antibiotics. Cells were pelleted and resuspended with 0.5 ml
of culture medium containing 12 lM ds-SiRNAs (Dharmacon, Chi-
cago, IL) against: c-Abl – 5 0AGGUGAAAAGCUCCGGGUC3 0
[14]; PKCd – 5 0GAUGAAGGAGGCGCUCAGC30 [15].
A SiRNA against luciferase 5 0CUUACGCUGAGUACUUCGA3 0
was used as control as already performed in the literature [14]. After
10 min of incubation on ice, cells were electroporated at 230 V and
resuspended in DMEM, 10% fetal calf serum without antibiotics. After
3–4 h, gentamycin and penicillin/streptomycin were added, and cells
were grown for 72 h at 37 C in the presence of 6% CO2.Fig. 1. Drugs induce apoptosis in Hep3B cells. Cells were exposed or not ()
measured by MTT assay, *P < 0.05, compared to basal (four experiments w
*P < 0.05, compared to basal (four independent experiments). (C) Chroma
Western blot of PARP cleavage (one typical experiment).2.8. Statistical analysis
Results are presented as means ± S.E.M. (n P 3). Statistical analy-
sis was performed with the Student’s t test considering P < 0.05 as
signiﬁcant.3. Results
3.1. Drugs induce apoptosis of Hep3B cells
Analysis by MTT assay of drug toxicity (Fig. 1A) showed
that the percentage of living cells was signiﬁcantly decreased
to 74.6 ± 8.8%, 29.6 ± 1.1% and 24.6 ± 7.7% after exposure
for 24 h to 1 lM DOX, 1 mM 5-FU or 1 mM cDDP, respec-
tively. As depicted in Fig. 1B, an increase of the subG1 phase
cell content was observed (9.8 ± 0.2%, 21.8 ± 8.5%, and
32.7 ± 1.4% for DOX, 5-FU and cDDP, respectively). DAPI
staining of nuclei revealed the formation of chromatin conden-
sation (Fig. 1C) and a cleavage of PARP into a fragment of
85 kDa was observed (Fig. 1D, see arrowhead).
3.2. SiRNAs and inhibitors against c-Abl and PKCd decrease
induction of apoptosis and ROS level
As assessed by Western blotting, the expression of the full
length 80-kDa PKCd and 145-kDa c-Abl (Fig. 2A and B) were
signiﬁcantly downregulated by transfection of Hep3B cells
with SiRNAs against these protein kinases. The PARP cleav-
age induced by DOX, cDDP or 5-FU was also completely
inhibited by SiRNAs (Fig. 3). Furthermore, as shown by the
MTT assay, the decrease by drugs of living cells was signiﬁ-
cantly restored by cell treatment with 5 lM rottlerin, or
10 lM Gleevec (Fig. 4A). Interestingly, these treatments also
slightly increased survival in cells not challenged with drugs,
suggesting that they might prevent spontaneous apoptosis.
This hypothesis is supported by the analyses by ﬂow cytometry
after PI staining of the basal subG1 phase which is lower in the
presence of Gleevec or rottlerin than in their absence
(Fig. 4B). These results also showed that the 5-FU-induced
subG1 phase was inhibited with percentages not signiﬁcantlyto 1 lMDOX, 1 mM 5-FU or 1 mM cDDP for 24 h. (A) Cell survival
ith three replicates). (B) SubG1 phase quantiﬁed by ﬂow cytometry,
tin condensation after DAPI staining (one typical experiment). (D)
Fig. 2. SiRNAs against PKCd (A) or c-Abl (B) inhibit their expres-
sions. Cells were transfected or not (WT) with anti-PKCd (ASPKCd)
or anti-c-Abl (ASc-Abl) SiRNAs. For control, SiRNAs against
luciferase (ASLC) were transfected [13]. The expressions of PKCd
and c-Abl were analyzed by Western blot (one typical experiment).
Anti-actin antibody was used as control.
Fig. 3. SiRNAs against c-Abl and PKCd inhibit PARP cleavage. Cells
transfected or not (WT) with SiRNAs against c-Abl (ASc-Abl) or
PKCd (ASPKCd) were exposed for 24 h to drugs. Nuclear lysates were
isolated and Western blots were performed (one typical experiment).
Fig. 4. Inhibitors against c-Abl and PKCd restore cell survival and
inhibit apoptosis. Cells were treated or not with 10 lM Gleevec and/
or 5 lM rottlerin for 15 min to 24 h [11,12] and were then exposed or
not () for 24 h to 1 lM DOX, 1 mM cDDP or 1 mM 5-FU for 24 h.
(A) Cell survival was measured by MTT assay (four experiments with
three replicates). (B) The subG1 phase was measured by ﬂow
cytometry after PI staining (three experiments).
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(6.2 ± 1.2%) alone or added together (6.5 ± 0.2%) (Fig. 4B).
Rottlerin or Gleevec had no signiﬁcant eﬀects on the basal
intracellular ROS level which corresponds to 21.1 ± 0.1% of
the 100% formation obtained with tert-butylhydroperoxide
(tert-butyl) (Fig. 5). After 3–7 h of exposure, according to
the drug, a maximal and signiﬁcant ROS increase correspond-
ing to a level of 25.7 ± 1.3% (DOX), 33.8 ± 3.3% (cDDP) and
30.8 ± 3.1% (5-FU), respectively, was observed. After cell pre-
treatment with Gleevec or rottlerin, the ROS generation
obtained under exposure to DOX, cDDP or 5-FU was de-
creased to a level of 20.1 ± 0.0%, 25.4 ± 0.8%, 20.8 ± 0.8%,
and 21.6 ± 0.3%, 28.3 ± 1.6% and 28.05 ± 0.7%, respectively.
3.3. Protein kinase c-Abl co-precipitates with PKCd and Bcl-XL/s
to mitochondria
After 90 min of cell exposure to drugs, an enriched mito-
chondrial fraction was obtained by centrifugations as de-
scribed under Section 2. The presence of a mitochondrial
enrichment was checked by Western blots using the strictly
mitochondrial markers, porin and COXIV. As shown in
Fig. 6A, the 31-kDa porin and the 19-kDa COXIV proteins
were observed in the pellet containing the puriﬁed mitochon-
drial fraction whereas, they are not present in the supernatant.
Immunoprecipitations performed from these mitochondrial
fractions, revealed the presence of the full length 145-kDa
c-Abl which was observed to be associated with the full length
Fig. 5. Inhibitors against c-Abl and PKCd inhibit ROS generation
induced by drugs. ROS level was measured using DCFH-DA.
*P < 0.05, compared to basal or to drug alone (four experiments with
seven replicates).
Fig. 7. Drugs induce a depolarization of the mitochondrial membrane.
Cells were exposed or not () for 24 h to drugs. The ﬂuorescence
intensity of DiOC6 was analyzed by ﬂow cytometry (three independent
experiments). For positive reference control (100%), CCCP was added
15 min before adding DiOC6.
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analyses of phosphorylations at the mitochondrial complex
level, showed a Ser-phosphorylation of c-Abl and a Tyr-phos-Fig. 6. Drugs induce co-precipitations and phosphorylations of c-Abl,
PKCd and Bcl-XL/s to mitochondria. (A) Enriched mitochondrial
fractions were prepared by centrifugations from cells and supernatant
(sup.) and pellet were checked by Western blots using antibodies
against porin or COXIV mitochondrial markers. (B) Mitochondrial
fractions were exposed or not () to drugs for 90 min and were then
immunoprecipitated (IP) without (c) or with anti-c-Abl antibody or
anti-PKCd antibodies. Western blots (WB) were revealed with anti-c-
Abl, anti-PKCd, anti-Bcl-XL/s, anti-Ser and anti-Tyr antibodies (one
typical experiment).phorylation of PKCd in the presence of DOX, cDDP and 5-
FU (Fig. 6B). In addition, a Ser-phosphorylation of Bcl-XL/s
was observed in the presence of DOX, cDDP and 5-FU
(Fig. 6B).
3.4. Drugs induce a decrease of MMP (DWm) and a stimulation
of caspase-2 and caspase-9
After a 24-h cell exposure to drugs, FACS analysis revealed
left shifts in the DiOC6 ﬂuorescence curve corresponding to a
disruption of the MMP. They correspond to 22.3 ± 4.2%,
42.2 ± 3.7%, 39.6 ± 2.2% and 43.0 ± 8.6% of depolarized cells
for basal, DOX, cDDP and 5-FU, respectively (Fig. 7). In
the same conditions, caspase-2 and -9 were activated with po-
tency ranges of 5-FU > DOX > cDDP and cDDP > 5-FU >
DOX, respectively (Fig. 8A and B).4. Discussion
DOX, cDDP or 5-FU are the most common DNA-damag-
ing agents used in chemotherapy. They induce apoptosis in tu-
moral cells through the activation of p53, p73, and/or Fas
receptor [1–3]. In the present study, we therefore investigated
the signaling pathways involved by these drugs to induce
apoptosis of Hep3B cells, which are devoid of these three
mediators.
A few studies using Hep3B cells have shown the induction of
apoptosis by DOX, cDDP or 5-FU [16,17]. We supported in
our ﬁrst set of experiments, that drugs induce apoptosis with
a range potency of cDDP > 5-FU > DOX. We therefore inves-
tigated the roles of protein kinases c-Abl and PKCd, suggested
to be implicated in stress-induced apoptosis by knocking down
their expressions by RNA interference. The complete inhibi-
tion of PARP cleavage suggested that both c-Abl and PKCd
could be involved in the induction of apoptosis by genotoxic
drugs in Hep3B cells, an hypothesis which is concordant with
observations found in other cells [8,18,19]. To corroborate
these results we used inhibitors which have been shown in
the literature to inhibit c-Abl and PKCd activities [11,12].
Fig. 8. Drugs activate caspase-2 (A) and caspase-9 (B). Cells were
exposed or not (basal) for 24 h to drugs. Caspase activities were
measured by spectroﬂuorimetry using Z-VDVAD-AFC or AC-LEHD-
AFC substrates, respectively (one typical experiment with seven
replicates).
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not exposed to drugs, suggesting that c-Abl may exert a pro-
apoptotic eﬀect in unstressed cells. A similar eﬀect has been ob-
served in pancreatic cells exposed to a low concentration of
Gleevec [20]. This could be explained by the fact that c-Abl
disables the NFjB survival pathway by phosphorylation of
IjB on Tyr305 increasing IjB stability and preventing NFjB
activity [21]. A blockade of this pathway by Gleevec could
be responsible for the increase in spontaneous Hep3B survival.
In our model, Gleevec was also able to prevent the induction
of apoptosis by 5-FU. Rottlerin alone or under drug treatment
was also found to increase the level of living cells and to block
the apoptosis induced by 5-FU. These observations are contra-
dictory with a recent ﬁnding showing that in haematopoietic
cell lines, rottlerin by itself was able to induce apoptosis
through caspases’ cascade [22].
Our ﬁndings were supporting the hypothesis that both c-Abl
and PKCd are involved in the induction by drugs of Hep3B cell
apoptosis. The percentages of inhibition of the 5-FU-induced
subG1 phase that we observed in the presence of Gleevec or
rottlerin, added alone, were not signiﬁcantly diﬀerent, even
when inhibitors were added together, suggesting that the activ-
ities of c-Abl and PKCd were not additive or synergic but bothseems to be required. The increase by drugs of the ROS level
that we observed could also play a major role in the mitochon-
drial permeability transition. As suggested in the literature,
ROS are able to trigger outer membrane rupture, cytochrome
c (cyt c) release, caspase-9 activation and apoptosis [23]. We
investigated whether both PKCd and c-Abl could be required
in the increase of ROS level that we observed after drug expo-
sure. We found that Gleevec or rottlerin, alone, had no eﬀect
on basal ROS level but inhibited the increase by drugs suggest-
ing the participation of PKCd and c-Abl in this pathway. A role
of a PKCd/c-Abl mitochondrial complex formation which
could be induced by drugs was therefore suspected. We found
that both protein kinases were present in the mitochondrial
fraction after exposure to drugs for 90 min. The presence of
PKCd in mitochondria had been observed after its overexpres-
sion in keratinocytes [24]. However, it is not yet known what
triggers the translocation of these two kinases to mitochondria.
It has been shown that c-abl can be sequestered or released
from 14-3-3 protein according to its phosphorylation state
[25]. However, it was not investigated whether this release al-
lows its translocation to mitochondria. Nor do we know how
PKCd and c-abl interact with each other to trigger apoptosis.
In cells exposed to ionizing radiation, c-Abl was found to bind,
phosphorylate and activate PKCd [19]. However, while the Tyr
phosphorylation of PKCd was required for the induction of
apoptosis by etoposide in one study [26], in another one, it
was independent of its kinase activity [27]. Our present studies
indicate that c-Abl could be responsible for Tyr phosphoryla-
tion of PKCd in the response to drugs. In the literature, a phos-
phorylation of PKCd on Tyr512 and Tyr523, has been shown to
be important for H2O2-induced activation [28]. Our ﬁndings
suggest that c-Abl was also phosphorylated by PKCd. It has
been suggested in the literature that protein kinase c-Abl could
be activated by Ser-phosphorylation after its interaction with
PKCd and subsequently phosphorylate PKCd at the Tyr512
[28]. Furthermore, we showed that c-Abl and PKCd also co-
precipitates with the anti-apoptotic protein, Bcl-XL/s. This sug-
gests that after its interaction with c-Abl and its activation,
PKCd was able to phosphorylate Bcl-XL/s. The Ser-phosphor-
ylation of Bcl-XL/s is known to inhibit its anti-apoptotic func-
tions [29]. The role of the mitochondria in the induction of
the apoptosis by drugs was supported by our ﬁndings showing
a disruption of the MMP and an activation of the caspase-2
activation known to permeabilize the outer mitochondrial
membrane and cause cyt c release and caspase-9 activation
which results from the formation of the apoptosome induced
by mitochondrial damage [30].
In conclusion, the present study suggests that both c-Abl
and PKCd could be required for the induction of apoptosis
by DOX, cDDP and 5-FU in Hep3B via the mitochondrial
pathway.
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